| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.godavaridrugs.com | |
| Market Cap | 59.72 Cr. | |
| Enterprise Value(EV) | 89.65 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 4.94 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 16.04 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 31.70 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 42.61 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 1.86 | Calculated using Price: 79.30 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 0.75 Cr. | 7,530,500 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company's principal activity is to manufacture and sell bulk drugs. It undertakes contract manufacturing from various organizations. The products include Pyrazinamide and Ethambutol HCL. | ||
| 1 Day |
|
+1.25% |
| 1 Week |
|
+4.07% |
| 1 Month |
|
-4.59% |
| 3 Month |
|
-12.44% |
| 6 Month |
|
+18.68% |
| 1 Year |
|
+33.82% |
| 2 Year |
|
+59.94% |
| 5 Year |
|
+150.51% |
| 10 Year |
|
+891.23% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 17.77 | 32.32 | 9.84 | 11.81 | 4.99 | 6.85 | 10.39 | 18.49 | 19.42 | |
| Return on Capital Employed (%) | 8.18 | 32.30 | 15.77 | 16.89 | 11.01 | 12.14 | 11.80 | 17.58 | 18.35 | |
| Return on Assets (%) | 10.41 | 14.70 | 3.17 | 3.41 | 1.40 | 1.77 | 2.54 | 4.72 | 5.45 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 10 | 13 | 14 | 16 | 17 | 18 | 20 | 24 | 30 | 31 | |
| Non Curr. Liab. | 2 | 5 | 5 | 6 | 9 | 9 | 12 | 16 | 14 | 13 | |
| Curr. Liab. | 3 | 17 | 31 | 34 | 37 | 46 | 51 | 51 | 58 | 79 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 124 | |
| Non Curr. Assets | 8 | 8 | 10 | 13 | 16 | 17 | 23 | 24 | 27 | 31 | |
| Curr. Assets | 6 | 27 | 40 | 43 | 47 | 56 | 61 | 68 | 74 | 93 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 124 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 9 | 55 | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 167 | |
| Other Income | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | |
| Total Income | 10 | 55 | 71 | 76 | 65 | 84 | 96 | 123 | 161 | 167 | |
| Total Expenditure | -8 | -49 | -67 | -70 | -60 | -78 | -90 | -113 | -150 | -157 | |
| PBIDT | 2 | 6 | 5 | 6 | 5 | 6 | 6 | 10 | 12 | 11 | |
| Interest | 0 | -1 | -2 | -3 | -2 | -3 | -3 | -3 | -3 | -4 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | |
| Taxation | 1 | -1 | -1 | -1 | 0 | -1 | 0 | -2 | -2 | -1 | |
| Exceptional Items | |||||||||||
| PAT | 2 | 4 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | |
| Adjusted EPS | 2 | 5 | 2 | 2 | 1 | 2 | 3 | 5 | 7 | 5 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 2 | -6 | -5 | 5 | 4 | 4 | 6 | 1 | 11 | |
| Cash Fr. Inv. | -1 | -2 | 0 | -2 | -3 | -3 | -2 | -7 | -1 | -5 | |
| Cash Fr. Finan. | 1 | 0 | 6 | 7 | -2 | 0 | -1 | 0 | 0 | -6 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | 2 |
|
Wed, 15 Mar 2023
Announcement under Regulation 30 (LODR)-Resignation of Director Revised Corporate announcement:Dear Sir/Madam This is with reference to the above captioned subject wherein we wish to inform that Mr. Dilip Keshavlal Patel Independent Directors of the Company have resigned w.e.f. 12/11/2022. The Company has filed their resignations with the Stock Exchange within stipulated time. However the Company has received emails dated 06th February 2023 wherein the Stock exchange has observed deficiency in said disclosures filed withall requisite details needed:Further we would like to bring to your kind notice that Mr. Dilip Keshavlal patel does not hold any directorship in Listed companies or membership of any Listed Company Board Committees at the time of his Resignation from the Company.Further the Company would like to hereby confirm that we have ratified the above filings and resubmitted the revised documents for which acknowledgement copy has been attached to this letter. |
|
Wed, 15 Feb 2023
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer Announcement under Regulation 30 (LODR)-Resignation of CS Rashmi Agarwal as Company Secretary & Compliance Officer of the Company w.e.f 14.02.2023. |
|
Tue, 14 Feb 2023
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer Announcement under Regulation 30 of LODR w.r.t Resignation of CS. Rashmi Agarwal as Company Secretary & Compliance officer of the Company. |
| Tue, 21 Mar 2023 |
High Decrease in 3 Months
|
High Increase in 1 Year
|
High Increase in 2 Years
|
High Increase in 5 Years
|
Closing Near 100 SMA
|
Equities
M.F.
Sectors